Nanil Therapeutics Inc
$75,000.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2025-2026
Canada
Nanil Therapeutics is validating its proprietary BioDesign-AI platform through experimental assessment of AI-generated nanobody sequences targeting tau, a key protein in Alzheimer’s disease.